Melvin E Andersen

List of Publications by Citations

500 papers	22,263 citations	76 h-index	123 g-index
538 ext. papers	24,391 ext. citations	4.7 avg, IF	6.61 L-index

#	Paper	IF	Citations
500	Recent advances in 2D and 3D in vitro systems using primary hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells and their use in investigating mechanisms of hepatotoxicity, cell signaling and ADME. *Archives of Toxicology*, **2013**, 87, 1315-530	5.8	837
499	A physiologically based description of the inhalation pharmacokinetics of styrene in rats and humans. *Toxicology and Applied Pharmacology*, **1984**, 73, 159-75	4.6	601
498	Physiologically based pharmacokinetics and the risk assessment process for methylene chloride. *Toxicology and Applied Pharmacology*, **1987**, 87, 185-205	4.6	524
497	Toxicity testing in the 21st century: a vision and a strategy. *Journal of Toxicology and Environmental Health - Part B: Critical Reviews*, **2010**, 13, 51-138	8.6	451
496	Partition coefficients of low-molecular-weight volatile chemicals in various liquids and tissues. *Toxicology and Applied Pharmacology*, **1989**, 98, 87-99	4.6	437
495	Reactive oxygen species as a signal in glucose-stimulated insulin secretion. *Diabetes*, **2007**, 56, 1783-91	0.9	402
494	Inhaled carbon nanotubes reach the subpleural tissue in mice. *Nature Nanotechnology*, **2009**, 4, 747-51	28.7	365
493	Human exposure and internal dose assessments of acrylamide in food. *Food and Chemical Toxicology*, **2005**, 43, 365-410	4.7	291
492	Integration of dosimetry, exposure, and high-throughput screening data in chemical toxicity assessment. *Toxicological Sciences*, **2012**, 125, 157-74	4.4	280
491	Organotypic liver culture models: meeting current challenges in toxicity testing. *Critical Reviews in Toxicology*, **2012**, 42, 501-48	5.7	252
490	ROS signaling, oxidative stress and Nrf2 in pancreatic beta-cell function. *Toxicology and Applied Pharmacology*, **2010**, 244, 77-83	4.6	248
489	Toxicity testing in the 21st century: bringing the vision to life. *Toxicological Sciences*, **2009**, 107, 324-30	4.4	236
488	Incorporating new technologies into toxicity testing and risk assessment: moving from 21st century vision to a data-driven framework. *Toxicological Sciences*, **2013**, 136, 4-18	4.4	195
487	Incorporating human dosimetry and exposure into high-throughput in vitro toxicity screening. *Toxicological Sciences*, **2010**, 117, 348-58	4.4	189
486	A physiologically based simulation approach for determining metabolic constants from gas uptake data. *Toxicology and Applied Pharmacology*, **1986**, 86, 341-52	4.6	175
485	A systems biology perspective on Nrf2-mediated antioxidant response. *Toxicology and Applied Pharmacology*, **2010**, 244, 84-97	4.6	173
484	Quantitative in vitro to in vivo extrapolation of cell-based toxicity assay results. *Critical Reviews in Toxicology*, **2012**, 42, 633-52	5.7	164

483	A physiologically based toxicokinetic model for the uptake and disposition of waterborne organic chemicals in fish. *Toxicology and Applied Pharmacology*, **1990**, 106, 433-47	4.6	159
482	Development of a physiologically based pharmacokinetic model for chloroform. *Toxicology and Applied Pharmacology*, **1990**, 103, 512-27	4.6	157
481	The acute toxicity of perfluorooctanoic and perfluorodecanoic acids in male rats and effects on tissue fatty acids. *Toxicology and Applied Pharmacology*, **1983**, 70, 362-72	4.6	154
480	Pharmacokinetic modeling of saturable, renal resorption of perfluoroalkylacids in monkeys--probing the determinants of long plasma half-lives. *Toxicology*, **2006**, 227, 156-64	4.4	151
479	Incorporating High-Throughput Exposure Predictions With Dosimetry-Adjusted In Vitro Bioactivity to Inform Chemical Toxicity Testing. *Toxicological Sciences*, **2015**, 148, 121-36	4.4	148
478	Toxicity testing in the 21 century: defining new risk assessment approaches based on perturbation of intracellular toxicity pathways. *PLoS ONE*, **2011**, 6, e20887	3.7	148
477	A method to integrate benchmark dose estimates with genomic data to assess the functional effects of chemical exposure. *Toxicological Sciences*, **2007**, 98, 240-8	4.4	144
476	Metabolism of inhaled dihalomethanes in vivo: differentiation of kinetic constants for two independent pathways. *Toxicology and Applied Pharmacology*, **1986**, 82, 211-23	4.6	142
475	Dose-dependent transitions in mechanisms of toxicity: case studies. *Toxicology and Applied Pharmacology*, **2004**, 201, 226-94	4.6	141
474	Dose-dependent transitions in mechanisms of toxicity. *Toxicology and Applied Pharmacology*, **2004**, 201, 203-25	4.6	137
473	Toxicokinetic modeling and its applications in chemical risk assessment. *Toxicology Letters*, **2003**, 138, 9-27	4.4	128
472	A physiologically based toxicokinetic description of the metabolism of inhaled gases and vapors: analysis at steady state. *Toxicology and Applied Pharmacology*, **1981**, 60, 509-26	4.6	124
471	Modeling receptor-mediated processes with dioxin: implications for pharmacokinetics and risk assessment. *Risk Analysis*, **1993**, 13, 25-36	3.9	122
470	Estimating the risk of liver cancer associated with human exposures to chloroform using physiologically based pharmacokinetic modeling. *Toxicology and Applied Pharmacology*, **1990**, 105, 443-59	4.6	120
469	A comprehensive statistical analysis of predicting in vivo hazard using high-throughput in vitro screening. *Toxicological Sciences*, **2012**, 128, 398-417	4.4	119
468	Quantitative interpretation of human biomonitoring data. *Toxicology and Applied Pharmacology*, **2008**, 231, 122-33	4.6	119
467	Risk assessment extrapolations and physiological modeling. *Toxicology and Industrial Health*, **1985**, 1, 111-31	1.8	119
466	Temporal concordance between apical and transcriptional points of departure for chemical risk assessment. *Toxicological Sciences*, **2013**, 134, 180-94	4.4	118

465	Ultrasensitive response motifs: basic amplifiers in molecular signalling networks. *Open Biology*, **2013**, 3, 130031	7	116
464	Physiologically based pharmacokinetic modeling with dichloromethane, its metabolite, carbon monoxide, and blood carboxyhemoglobin in rats and humans. *Toxicology and Applied Pharmacology*, **1991**, 108, 14-27	4.6	116
463	Glutathione S-transferase-mediated mutagenicity of trihalomethanes in Salmonella typhimurium: contrasting results with bromodichloromethane off chloroform. *Toxicology and Applied Pharmacology*, **1997**, 144, 183-8	4.6	115
462	Physiologically based pharmacokinetic modeling of the pregnant rat: a multiroute exposure model for trichloroethylene and its metabolite, trichloroacetic acid. *Toxicology and Applied Pharmacology*, **1989**, 99, 395-414	4.6	114
461	An overview of chemical inhibitors of the Nrf2-ARE signaling pathway and their potential applications in cancer therapy. *Free Radical Biology and Medicine*, **2016**, 99, 544-556	7.8	111
460	Pharmacokinetic data needs to support risk assessments for inhaled and ingested manganese. *NeuroToxicology*, **1999**, 20, 161-71	4.4	111
459	Associations of Perfluoroalkyl Substances (PFAS) with Lower Birth Weight: An Evaluation of Potential Confounding by Glomerular Filtration Rate Using a Physiologically Based Pharmacokinetic Model (PBPK). *Environmental Health Perspectives*, **2015**, 123, 1317-24	8.4	110
458	Adipose deficiency of Nrf2 in ob/ob mice results in severe metabolic syndrome. *Diabetes*, **2013**, 62, 845-54	8.1	110
457	Toxicity testing in the 21st century: implications for human health risk assessment. *Risk Analysis*, **2009**, 29, 474-9	3.9	105
456	Formaldehyde: integrating dosimetry, cytotoxicity, and genomics to understand dose-dependent transitions for an endogenous compound. *Toxicological Sciences*, **2010**, 118, 716-31	4.4	102
455	Characterizing uncertainty and variability in physiologically based pharmacokinetic models: state of the science and needs for research and implementation. *Toxicological Sciences*, **2007**, 99, 395-402	4.4	102
454	Low-level arsenic impairs glucose-stimulated insulin secretion in pancreatic beta cells: involvement of cellular adaptive response to oxidative stress. *Environmental Health Perspectives*, **2010**, 118, 864-70	8.4	101
453	Implementing Toxicity Testing in the 21st Century (TT21C): Making safety decisions using toxicity pathways, and progress in a prototype risk assessment. *Toxicology*, **2015**, 332, 102-11	4.4	100
452	Determination of the kinetic constants for metabolism of inhaled toxicants in vivo using gas uptake measurements. *Toxicology and Applied Pharmacology*, **1980**, 54, 100-16	4.6	100
451	Application of transcriptional benchmark dose values in quantitative cancer and noncancer risk assessment. *Toxicological Sciences*, **2011**, 120, 194-205	4.4	98
450	A physiological pharmacokinetic description of the tissue distribution and enzyme-inducing properties of 2,3,7,8-tetrachlorodibenzo-p-dioxin in the rat. *Toxicology and Applied Pharmacology*, **1990**, 103, 399-410	4.6	96
449	Toxicity testing in the 21st century: progress in the past decade and future perspectives. *Archives of Toxicology*, **2020**, 94, 1-58	5.8	96
448	Nuclear factor erythroid-derived factor 2-related factor 2 regulates transcription of CCAAT/enhancer-binding protein □during adipogenesis. *Free Radical Biology and Medicine*, **2012**, 52, 462-72	7.8	94

447	Physiologically based pharmacokinetic and pharmacodynamic model for the inhibition of acetylcholinesterase by diisopropylfluorophosphate. *Toxicology and Applied Pharmacology*, **1990**, 106, 295-310	4.6	94
446	Development of PBPK models for PFOA and PFOS for human pregnancy and lactation life stages. *Journal of Toxicology and Environmental Health - Part A: Current Issues*, **2013**, 76, 25-57	3.2	93
445	Quantitative evaluation of the metabolic interactions between trichloroethylene and 1,1-dichloroethylene in vivo using gas uptake methods. *Toxicology and Applied Pharmacology*, **1987**, 89, 149-57	4.6	93
444	Relative impact of incorporating pharmacokinetics on predicting in vivo hazard and mode of action from high-throughput in vitro toxicity assays. *Toxicological Sciences*, **2013**, 132, 327-46	4.4	92
443	Comparison of cancer risk estimates for vinyl chloride using animal and human data with a PBPK model. *Science of the Total Environment*, **2001**, 274, 37-66	10.2	91
442	Dermal absorption of organic chemical vapors in rats and humans. *Fundamental and Applied Toxicology*, **1990**, 14, 299-308		91
441	A physiologically based pharmacokinetic model for inhaled carbon tetrachloride. *Toxicology and Applied Pharmacology*, **1988**, 96, 191-211	4.6	85
440	A deterministic map of Waddington's epigenetic landscape for cell fate specification. *BMC Systems Biology*, **2011**, 5, 85	3.5	84
439	Use of physiologically based pharmacokinetic modeling to investigate individual versus population risk. *Toxicology*, **1996**, 111, 315-29	4.4	84
438	In vitro to in vivo extrapolation and species response comparisons for drug-induced liver injury (DILI) using DILIsym□a mechanistic, mathematical model of DILI. *Journal of Pharmacokinetics and Pharmacodynamics*, **2012**, 39, 527-41	2.7	83
437	Incorporation of in vitro enzyme data into the physiologically-based pharmacokinetic (PB-PK) model for methylene chloride: implications for risk assessment. *Toxicology Letters*, **1988**, 43, 97-116	4.4	83
436	A physiological pharmacokinetic model for dermal absorption of vapors in the rat. *Toxicology and Applied Pharmacology*, **1986**, 85, 286-94	4.6	82
435	The Dissociation of the First Oxygen Molecule from Some Mammalian Oxyhemoglobins. *Journal of Biological Chemistry*, **1971**, 246, 5919-5923	5.4	81
434	New directions in toxicity testing. *Annual Review of Public Health*, **2011**, 32, 161-78	20.6	80
433	Evaluation and prediction of pharmacokinetics of PFOA and PFOS in the monkey and human using a PBPK model. *Regulatory Toxicology and Pharmacology*, **2011**, 59, 157-75	3.4	80
432	Physiologically based pharmacokinetic modeling of fetal and neonatal manganese exposure in humans: describing manganese homeostasis during development. *Toxicological Sciences*, **2011**, 122, 297-316	4.4	80
431	Linear low-dose extrapolation for noncancer heath effects is the exception, not the rule. *Critical Reviews in Toxicology*, **2011**, 41, 1-19	5.7	80
430	A physiologically based pharmacokinetic model for 2,3,7,8-tetrachlorodibenzo-p-dioxin in C57BL/6J and DBA/2J mice. *Toxicology Letters*, **1988**, 42, 15-28	4.4	80

429	A map of the PPARα transcription regulatory network for primary human hepatocytes. *Chemico-Biological Interactions*, **2014**, 209, 14-24	5	79
428	A physiologically based pharmacokinetic and pharmacodynamic model to describe the oral dosing of rats with ethyl acrylate and its implications for risk assessment. *Toxicology and Applied Pharmacology*, **1992**, 114, 246-60	4.6	79
427	The vision of toxicity testing in the 21st century: moving from discussion to action. *Toxicological Sciences*, **2010**, 117, 17-24	4.4	78
426	Physiologically based pharmacokinetic modeling with trichloroethylene and its metabolite, trichloroacetic acid, in the rat and mouse. *Toxicology and Applied Pharmacology*, **1991**, 109, 183-95	4.6	78
425	Regional hepatic CYP1A1 and CYP1A2 induction with 2,3,7,8-tetrachlorodibenzo-p-dioxin evaluated with a multicompartment geometric model of hepatic zonation. *Toxicology and Applied Pharmacology*, **1997**, 144, 145-55	4.6	76
424	Physiologically based pharmacokinetic modeling of the lactating rat and nursing pup: a multiroute exposure model for trichloroethylene and its metabolite, trichloroacetic acid. *Toxicology and Applied Pharmacology*, **1990**, 102, 497-513	4.6	76
423	Integrating pathway-based transcriptomic data into quantitative chemical risk assessment: a five chemical case study. *Mutation Research - Genetic Toxicology and Environmental Mutagenesis*, **2012**, 746, 135-43	3	75
422	Modeling the tissue solubilities and metabolic rate constant (Vmax) of halogenated methanes, ethanes, and ethylenes. *Toxicology Letters*, **1988**, 43, 235-56	4.4	75
421	Genomic signatures and dose-dependent transitions in nasal epithelial responses to inhaled formaldehyde in the rat. *Toxicological Sciences*, **2008**, 105, 368-83	4.4	73
420	Dose response relationship in anti-stress gene regulatory networks. *PLoS Computational Biology*, **2007**, 3, e24	5	73
419	In vitro human tissue models in risk assessment: report of a consensus-building workshop. *Toxicological Sciences*, **2001**, 59, 17-36	4.4	72
418	Pharmacokinetics of tetrachloroethylene. *Toxicology and Applied Pharmacology*, **1988**, 93, 108-17	4.6	72
417	A framework for the next generation of risk science. *Environmental Health Perspectives*, **2014**, 122, 796-805	8.4	71
416	Prolonged inorganic arsenite exposure suppresses insulin-stimulated AKT S473 phosphorylation and glucose uptake in 3T3-L1 adipocytes: involvement of the adaptive antioxidant response. *Biochemical and Biophysical Research Communications*, **2011**, 407, 360-5	3.4	71
415	A consistent approach for the application of pharmacokinetic modeling in cancer and noncancer risk assessment. *Environmental Health Perspectives*, **2002**, 110, 85-93	8.4	71
414	Considering pharmacokinetic and mechanistic information in cancer risk assessments for environmental contaminants: examples with vinyl chloride and trichloroethylene. *Chemosphere*, **1995**, 31, 2561-78	8.4	71
413	Development of a physiologically based pharmacokinetic model for risk assessment with 1,4-dioxane. *Toxicology and Applied Pharmacology*, **1990**, 105, 37-54	4.6	71
412	Toxic effects of nonadecafluoro-n-decanoic acid in rats. *Toxicology and Applied Pharmacology*, **1986**, 85, 169-80	4.6	70

411	Sensitivity analysis of a physiological model for 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD): assessing the impact of specific model parameters on sequestration in liver and fat in the rat. *Toxicological Sciences*, **2000**, 54, 71-80	4.4	69
410	Dose-dependent transitions in Nrf2-mediated adaptive response and related stress responses to hypochlorous acid in mouse macrophages. *Toxicology and Applied Pharmacology*, **2009**, 238, 27-36	4.6	67
409	Long isoforms of NRF1 contribute to arsenic-induced antioxidant response in human keratinocytes. *Environmental Health Perspectives*, **2011**, 119, 56-62	8.4	67
408	Predicting cancer risk from vinyl chloride exposure with a physiologically based pharmacokinetic model. *Toxicology and Applied Pharmacology*, **1996**, 137, 253-67	4.6	67
407	A physiologically based pharmacokinetic model for nicotine disposition in the Sprague-Dawley rat. *Toxicology and Applied Pharmacology*, **1992**, 116, 177-88	4.6	67
406	In vivo metabolic interactions of benzene and toluene. *Toxicology Letters*, **1990**, 52, 141-52	4.4	67
405	Adverse Outcome Pathways can drive non-animal approaches for safety assessment. *Journal of Applied Toxicology*, **2015**, 35, 971-5	4.1	66
404	Saturable metabolism and its relationship to toxicity. *CRC Critical Reviews in Toxicology*, **1981**, 9, 105-50		66
403	Quantitative analyses and transcriptomic profiling of circulating messenger RNAs as biomarkers of rat liver injury. *Hepatology*, **2010**, 51, 2127-39	11.2	64
402	Development of physiologically based pharmacokinetic and physiologically based pharmacodynamic models for applications in toxicology and risk assessment. *Toxicology Letters*, **1995**, 79, 35-44	4.4	63
401	Biologically based pharmacodynamic models: tools for toxicological research and risk assessment. *Annual Review of Pharmacology and Toxicology*, **1991**, 31, 503-23	17.9	63
400	Evaluating placental transfer and tissue concentrations of manganese in the pregnant rat and fetuses after inhalation exposures with a PBPK model. *Toxicological Sciences*, **2009**, 112, 44-58	4.4	62
399	In vitro metabolism of di(2-ethylhexyl) phthalate (DEHP) by various tissues and cytochrome P450s of human and rat. *Toxicology in Vitro*, **2012**, 26, 315-22	3.6	61
398	Development of a physiologically based pharmacokinetic model of isopropanol and its metabolite acetone. *Toxicological Sciences*, **2001**, 63, 160-72	4.4	61
397	A physiologically based pharmacokinetic model for 2,3,7,8-tetrabromodibenzo-p-dioxin (TBDD) in the rat: tissue distribution and CYP1A induction. *Toxicology and Applied Pharmacology*, **1993**, 121, 87-98	4.6	61
396	An analysis of N-acetylcysteine treatment for acetaminophen overdose using a systems model of drug-induced liver injury. *Journal of Pharmacology and Experimental Therapeutics*, **2012**, 342, 529-40	4.7	60
395	Tissue exposures to free and glucuronidated monobutylyphthalate in the pregnant and fetal rat following exposure to di-n-butylphthalate: evaluation with a PBPK model. *Toxicological Sciences*, **2008**, 103, 241-59	4.4	60
394	Non-monotonic dose-response relationship in steroid hormone receptor-mediated gene expression. *Journal of Molecular Endocrinology*, **2007**, 38, 569-85	4.5	60

393	Physiologically based pharmacokinetic modeling of styrene and styrene oxide respiratory-tract dosimetry in rodents and humans. *Inhalation Toxicology*, **2002**, 14, 789-834	2.7	60
392	The dissociation of the first oxygen molecule from some mammalian oxyhemoglobins. *Journal of Biological Chemistry*, **1971**, 246, 5919-23	5.4	60
391	Evidence that atrazine and diaminochlorotriazine inhibit the estrogen/progesterone induced surge of luteinizing hormone in female Sprague-Dawley rats without changing estrogen receptor action. *Toxicological Sciences*, **2004**, 79, 278-86	4.4	59
390	Inhalation pharmacokinetics: evaluating systemic extraction, total in vivo metabolism, and the time course of enzyme induction for inhaled styrene in rats based on arterial blood:inhaled air concentration ratios. *Toxicology and Applied Pharmacology*, **1984**, 73, 176-87	4.6	59
389	Pathways of Toxicity. *ALTEX: Alternatives To Animal Experimentation*, **2014**, 31, 53-61	4.3	59
388	The Next Generation of Risk Assessment Multi-Year Study-Highlights of Findings, Applications to Risk Assessment, and Future Directions. *Environmental Health Perspectives*, **2016**, 124, 1671-1682	8.4	59
387	Co-culture of Hepatocytes and Kupffer Cells as an In Vitro Model of Inflammation and Drug-Induced Hepatotoxicity. *Journal of Pharmaceutical Sciences*, **2016**, 105, 950-964	3.9	58
386	Applying simulation modeling to problems in toxicology and risk assessment--a short perspective. *Toxicology and Applied Pharmacology*, **1995**, 133, 181-7	4.6	58
385	Assessing the relevance of in vitro measures of phthalate inhibition of steroidogenesis for in vivo response. *Toxicology in Vitro*, **2010**, 24, 327-34	3.6	57
384	Physiologically based modeling of vinyl acetate uptake, metabolism, and intracellular pH changes in the rat nasal cavity. *Toxicology and Applied Pharmacology*, **1997**, 142, 386-400	4.6	57
383	The use of Markov chain Monte Carlo uncertainty analysis to support a Public Health Goal for perchloroethylene. *Regulatory Toxicology and Pharmacology*, **2007**, 47, 1-18	3.4	57
382	Time dependencies in perfluorooctylacids disposition in rat and monkeys: a kinetic analysis. *Toxicology Letters*, **2008**, 177, 38-47	4.4	56
381	Modeling of human dermal absorption of octamethylcyclotetrasiloxane (D(4)) and decamethylcyclopentasiloxane (D(5)). *Toxicological Sciences*, **2007**, 99, 422-31	4.4	56
380	A biologically based risk assessment for vinyl acetate-induced cancer and noncancer inhalation toxicity. *Toxicological Sciences*, **1999**, 51, 19-35	4.4	56
379	Gas Uptake Inhalation Techniques and the Rates of Metabolism of Chloromethanes, Chloroethanes, and Chloroethylenes in the Rat. *Inhalation Toxicology*, **1990**, 2, 295-319	2.7	56
378	A physiologically based description of ethylene oxide dosimetry in the rat. *Toxicology and Industrial Health*, **1992**, 8, 121-40	1.8	55
377	Activation of Nrf2-mediated oxidative stress response in macrophages by hypochlorous acid. *Toxicology and Applied Pharmacology*, **2008**, 226, 236-43	4.6	54
376	Negative selection in hepatic tumor promotion in relation to cancer risk assessment. *Toxicology*, **1995**, 102, 223-37	4.4	53

375	Defining and modeling known adverse outcome pathways: Domoic acid and neuronal signaling as a case study. *Environmental Toxicology and Chemistry*, **2011**, 30, 9-21	3.8	52
374	Analysis of manganese tracer kinetics and target tissue dosimetry in monkeys and humans with multi-route physiologically based pharmacokinetic models. *Toxicological Sciences*, **2011**, 120, 481-98	4.4	52
373	A physiologically based pharmacokinetic model for retinoic acid and its metabolites. *Journal of the American Academy of Dermatology*, **1997**, 36, S77-85	4.5	52
372	Molecular signaling network motifs provide a mechanistic basis for cellular threshold responses. *Environmental Health Perspectives*, **2014**, 122, 1261-70	8.4	51
371	In silico toxicology: simulating interaction thresholds for human exposure to mixtures of trichloroethylene, tetrachloroethylene, and 1,1,1-trichloroethane. *Environmental Health Perspectives*, **2002**, 110, 1031-9	8.4	51
370	Comparison and evaluation of pharmacokinetics of PFOA and PFOS in the adult rat using a physiologically based pharmacokinetic model. *Reproductive Toxicology*, **2012**, 33, 452-467	3.4	50
369	Deficiency in the nuclear factor E2-related factor 2 renders pancreatic β-cells vulnerable to arsenic-induced cell damage. *Toxicology and Applied Pharmacology*, **2012**, 264, 315-23	4.6	50
368	Long-term stability of primary rat hepatocytes in micropatterned cocultures. *Journal of Biochemical and Molecular Toxicology*, **2013**, 27, 204-12	3.4	50
367	Phase I to II cross-induction of xenobiotic metabolizing enzymes: a feedforward control mechanism for potential hormetic responses. *Toxicology and Applied Pharmacology*, **2009**, 237, 345-56	4.6	50
366	Cross-regulations among NRFs and KEAP1 and effects of their silencing on arsenic-induced antioxidant response and cytotoxicity in human keratinocytes. *Environmental Health Perspectives*, **2012**, 120, 583-9	8.4	50
365	Application of pharmacokinetic data to the risk assessment of inhaled manganese. *NeuroToxicology* , **2006**, 27, 752-64	4.4	50
364	Pharmacokinetics of [125I]-2-iodo-3,7,8-trichlorodibenzo-p-dioxin in mice: analysis with a physiological modeling approach. *Toxicology and Applied Pharmacology*, **1990**, 103, 411-9	4.6	50
363	Adjusting exposure limits for long and short exposure periods using a physiological pharmacokinetic model. *AIHA Journal*, **1987**, 48, 335-43		50
362	Toxicology of cyclotrimethylenetrinitramine: distribution and metabolism in the rat and the miniature swine. *Toxicology and Applied Pharmacology*, **1977**, 39, 531-41	4.6	50
361	Physiological model for tissue glutathione depletion and increased resynthesis after ethylene dichloride exposure. *Journal of Pharmacology and Experimental Therapeutics*, **1988**, 245, 563-8	4.7	50
360	Association between arsenic suppression of adipogenesis and induction of CHOP10 via the endoplasmic reticulum stress response. *Environmental Health Perspectives*, **2013**, 121, 237-43	8.4	49
359	Physiological modelling of organic compounds. *Annals of Occupational Hygiene*, **1991**, 35, 309-21		49
358	A Kinetic Analysis of the Binding of Oxygen and Carbon Monoxide to Lamprey Hemoglobin. *Journal of Biological Chemistry*, **1971**, 246, 4790-4799	5.4	49

357	Regulatory role of KEAP1 and NRF2 in PPAR expression and chemoresistance in human non-small-cell lung carcinoma cells. *Free Radical Biology and Medicine*, **2012**, 53, 758-68	7.8	48
356	Modeling drug- and chemical-induced hepatotoxicity with systems biology approaches. *Frontiers in Physiology*, **2012**, 3, 462	4.6	48
355	Application of a physiologically based pharmacokinetic model for isopropanol in the derivation of a reference dose and reference concentration. *Regulatory Toxicology and Pharmacology*, **2002**, 36, 51-68	3.4	48
354	Pathological and hepatic ultrastructural effects of a single dose of perfluoro-n-decanoic acid in the rat, hamster, mouse, and guinea pig. *Fundamental and Applied Toxicology*, **1987**, 9, 522-540		48
353	Genetic variability in a frozen batch of MCF-7 cells invisible in routine authentication affecting cell function. *Scientific Reports*, **2016**, 6, 28994	4.9	47
352	Evaluation of placental and lactational pharmacokinetics of PFOA and PFOS in the pregnant, lactating, fetal and neonatal rat using a physiologically based pharmacokinetic model. *Reproductive Toxicology*, **2012**, 33, 468-490	3.4	47
351	Adaptive Posttranslational Control in Cellular Stress Response Pathways and Its Relationship to Toxicity Testing and Safety Assessment. *Toxicological Sciences*, **2015**, 147, 302-16	4.4	46
350	A multicompartment geometric model of the liver in relation to regional induction of cytochrome P450s. *Toxicology and Applied Pharmacology*, **1997**, 144, 135-44	4.6	46
349	The use of inhalation techniques to assess the kinetic constants of 1,1-dichloroethylene metabolism. *Toxicology and Applied Pharmacology*, **1979**, 47, 395-409	4.6	46
348	CNC-bZIP protein Nrf1-dependent regulation of glucose-stimulated insulin secretion. *Antioxidants and Redox Signaling*, **2015**, 22, 819-31	8.4	45
347	Reply to Invited Commentaries on Toxicity Testing in the 21st Century: Implications for Human Health Risk Assessment. *Risk Analysis*, **2009**, 29, 492-497	3.9	45
346	Characterization of the pharmacokinetics of gasoline using PBPK modeling with a complex mixtures chemical lumping approach. *Inhalation Toxicology*, **2003**, 15, 961-86	2.7	45
345	Assessing interaction thresholds for trichloroethylene in combination with tetrachloroethylene and 1,1,1-trichloroethane using gas uptake studies and PBPK modeling. *Archives of Toxicology*, **2001**, 75, 134-44	5.8	45
344	Dermal absorption and penetration of jet fuel components in humans. *Toxicology Letters*, **2006**, 165, 11-21	4.4	43
343	A physiologically based pharmacokinetic model for acrylamide and its metabolite, glycidamide, in the rat. *Journal of Toxicology and Environmental Health - Part A: Current Issues*, **2003**, 66, 253-74	3.2	43
342	The human toxome project. *ALTEX: Alternatives To Animal Experimentation*, **2015**, 32, 112-24	4.3	43
341	Computational systems biology and dose-response modeling in relation to new directions in toxicity testing. *Journal of Toxicology and Environmental Health - Part B: Critical Reviews*, **2010**, 13, 253-76	8.6	42
340	The future of toxicity testing. *Journal of Toxicology and Environmental Health - Part B: Critical Reviews*, **2010**, 13, 163-96	8.6	42

339	Hepatic foci in rats after diethylnitrosamine initiation and 2,3,7,8-tetrachlorodibenzo-p-dioxin promotion: evaluation of a quantitative two-cell model and of CYP 1A1/1A2 as a dosimeter. *Toxicology and Applied Pharmacology*, **1997**, 146, 281-93	4.6	42
338	Physiological modeling reveals novel pharmacokinetic behavior for inhaled octamethylcyclotetrasiloxane in rats. *Toxicological Sciences*, **2001**, 60, 214-31	4.4	42
337	Pharmacokinetic modeling of manganese in the rat IV: Assessing factors that contribute to brain accumulation during inhalation exposure. *Journal of Toxicology and Environmental Health - Part A: Current Issues*, **2008**, 71, 413-26	3.2	41
336	Pharmacokinetic modeling of disposition and time-course studies with [14C]atrazine. *Journal of Toxicology and Environmental Health - Part A: Current Issues*, **2003**, 66, 941-64	3.2	41
335	New directions in incidence-dose modeling. *Trends in Biotechnology*, **2005**, 23, 122-7	15.1	41
334	Detection and localization of an estrogen receptor beta splice variant protein (ERbeta2) in the adult female rat forebrain and midbrain regions. *Journal of Comparative Neurology*, **2007**, 505, 249-67	3.4	40
333	Pharmacokinetics, biochemical mechanism and mutation accumulation: a comprehensive model of chemical carcinogenesis. *Toxicology Letters*, **1988**, 43, 189-200	4.4	40
332	Mutagenicity of trans-anethole, estragole, eugenol, and safrole in the Ames Salmonella typhimurium assay. *Bulletin of Environmental Contamination and Toxicology*, **1982**, 28, 647-54	2.7	40
331	Enhancing and Extending Biological Performance and Resilience. *Dose-Response*, **2018**, 16, 1559325818784501	2.3	40
330	Is the relationship between prenatal exposure to PCB-153 and decreased birth weight attributable to pharmacokinetics?. *Environmental Health Perspectives*, **2013**, 121, 1219-24	8.4	39
329	Manganese tissue dosimetry in rats and monkeys: accounting for dietary and inhaled Mn with physiologically based pharmacokinetic modeling. *Toxicological Sciences*, **2009**, 108, 22-34	4.4	39
328	Tissue dosimetry, pharmacokinetic modeling, and interspecies scaling factors. *Risk Analysis*, **1995**, 15, 533-7	3.9	39
327	A mechanistic redefinition of adverse effects - a key step in the toxicity testing paradigm shift. *ALTEX: Alternatives To Animal Experimentation*, **2010**, 27, 243-52	4.3	39
326	Profiling dose-dependent activation of p53-mediated signaling pathways by chemicals with distinct mechanisms of DNA damage. *Toxicological Sciences*, **2014**, 142, 56-73	4.4	38
325	Genome-wide analysis of DNA methylation and gene expression changes in the mouse lung following subchronic arsenate exposure. *Toxicological Sciences*, **2010**, 117, 404-17	4.4	38
324	Hormesis and adaptive cellular control systems. *Dose-Response*, **2008**, 6, 196-208	2.3	38
323	Physiologically based pharmacokinetic/pharmacodynamic modeling of the toxicologic interaction between carbon tetrachloride and Kepone. *Archives of Toxicology*, **1996**, 70, 704-13	5.8	38
322	Use of short-term transcriptional profiles to assess the long-term cancer-related safety of environmental and industrial chemicals. *Toxicological Sciences*, **2009**, 112, 311-21	4.4	37

321	Physiologically based estimation of in vivo rates of bromodichloromethane metabolism. *Toxicology*, **1997**, 124, 141-52	4.4	37
320	The need for a new toxicity testing and risk analysis paradigm to implement REACH or any other large scale testing initiative. *Archives of Toxicology*, **2007**, 81, 385-7	5.8	37
319	Physiological modeling of inhalation kinetics of octamethylcyclotetrasiloxane in humans during rest and exercise. *Toxicological Sciences*, **2003**, 72, 3-18	4.4	37
318	The significance of multiple detoxification pathways for reactive metabolites in the toxicity of 1,1-dichloroethylene. *Toxicology and Applied Pharmacology*, **1980**, 52, 422-32	4.6	37
317	Evaluating transport of manganese from olfactory mucosa to striatum by pharmacokinetic modeling. *Toxicological Sciences*, **2007**, 97, 265-78	4.4	36
316	Determining kinetic constants of chlorinated ethane metabolism in the rat from rates of exhalation. *Toxicology and Applied Pharmacology*, **1989**, 99, 344-53	4.6	36
315	Perfluoro-n-decanoic acid: induction of peroxisomal beta-oxidation by a fatty acid with dioxin-like toxicity. *Lipids*, **1988**, 23, 115-9	1.6	36
314	Studies on Ligand Binding to Hemoglobins from Teleosts and Elasmobranchs. *Journal of Biological Chemistry*, **1973**, 248, 331-341	5.4	36
313	Incorporation of tissue reaction kinetics in a computational fluid dynamics model for nasal extraction of inhaled hydrogen sulfide in rats. *Toxicological Sciences*, **2006**, 90, 198-207	4.4	35
312	Evaluation of physiologically based pharmacokinetic models in risk assessment: an example with perchloroethylene. *Critical Reviews in Toxicology*, **2005**, 35, 413-33	5.7	35
311	Gas uptake studies of deuterium isotope effects on dichloromethane metabolism in female B6C3F1 mice in vivo. *Toxicology and Applied Pharmacology*, **1994**, 128, 158-65	4.6	35
310	Metabolism of inhaled brominated hydrocarbons: validation of gas uptake results by determination of a stable metabolite. *Toxicology and Applied Pharmacology*, **1982**, 66, 55-68	4.6	35
309	A biologically based dose-response model for dietary iodide and the hypothalamic-pituitary-thyroid axis in the adult rat: evaluation of iodide deficiency. *Toxicological Sciences*, **2008**, 102, 241-53	4.4	34
308	A physiologically based dosimetry description of acrylonitrile and cyanoethylene oxide in the rat. *Toxicology and Applied Pharmacology*, **1995**, 134, 185-94	4.6	34
307	Physiologically based pharmacokinetic model for vinylidene chloride. *Toxicology and Applied Pharmacology*, **1988**, 95, 230-40	4.6	34
306	Potentiation of 2,5-hexanedione neurotoxicity by methyl ethyl ketone. *Toxicology and Applied Pharmacology*, **1985**, 81, 319-27	4.6	34
305	Can case study approaches speed implementation of the NRC report: "toxicity testing in the 21st century: a vision and a strategy?". *ALTEX: Alternatives To Animal Experimentation*, **2011**, 28, 175-82	4.3	34
304	Effects of endogenous formaldehyde in nasal tissues on inhaled formaldehyde dosimetry predictions in the rat, monkey, and human nasal passages. *Toxicological Sciences*, **2014**, 138, 412-24	4.4	33

303	Iodoacetic acid activates Nrf2-mediated antioxidant response in vitro and in vivo. *Environmental Science & Technology*, **2014**, 48, 13478-88	10.3	33
302	In vitro intestinal and hepatic metabolism of Di(2-ethylhexyl) phthalate (DEHP) in human and rat. *Toxicology in Vitro*, **2013**, 27, 1451-7	3.6	33
301	A bistable switch underlying B-cell differentiation and its disruption by the environmental contaminant 2,3,7,8-tetrachlorodibenzo-p-dioxin. *Toxicological Sciences*, **2010**, 115, 51-65	4.4	33
300	Competitive inhibition of thyroidal uptake of dietary iodide by perchlorate does not describe perturbations in rat serum total T4 and TSH. *Environmental Health Perspectives*, **2009**, 117, 731-8	8.4	33
299	Mode of action and tissue dosimetry in current and future risk assessments. *Science of the Total Environment*, **2001**, 274, 3-14	10.2	33
298	Evidence-based toxicology for the 21st century: opportunities and challenges. *ALTEX: Alternatives To Animal Experimentation*, **2013**, 30, 74-103	4.3	33
297	Can the observed association between serum perfluoroalkyl substances and delayed menarche be explained on the basis of puberty-related changes in physiology and pharmacokinetics?. *Environment International*, **2015**, 82, 61-8	12.9	32
296	A physiologically based pharmacokinetic description of the oral uptake, tissue dosimetry, and rates of metabolism of bromodichloromethane in the male rat. *Toxicology and Applied Pharmacology*, **1998**, 150, 205-17	4.6	32
295	Evaluation of potential toxicity from co-exposure to three CNS depressants (toluene, ethylbenzene, and xylene) under resting and working conditions using PBPK modeling. *Journal of Occupational and Environmental Hygiene*, **2005**, 2, 127-35	2.9	32
294	Physiologically based pharmacokinetic (PBPK) models for nasal tissue dosimetry of organic esters: assessing the state-of-knowledge and risk assessment applications with methyl methacrylate and vinyl acetate. *Regulatory Toxicology and Pharmacology*, **2002**, 36, 234-45	3.4	32
293	Physiological pharmacokinetics and cancer risk assessment. *Cancer Letters*, **1993**, 69, 1-14	9.9	31
292	Application of biologically based computer modeling to simple or complex mixtures. *Environmental Health Perspectives*, **2002**, 110 Suppl 6, 957-63	8.4	30
291	Chemical mixture toxicology: from descriptive to mechanistic, and going on to in silico toxicology. *Environmental Toxicology and Pharmacology*, **2004**, 18, 65-81	5.8	30
290	Physiologically-based pharmacokinetic modeling and bioactivation of xenobiotics. *Toxicology and Industrial Health*, **1994**, 10, 1-24	1.8	30
289	Saturable metabolism and the acute toxicity of 1,1-dichloroethylene. *Toxicology and Applied Pharmacology*, **1979**, 47, 385-93	4.6	30
288	Toxicokinetics and physiologically based toxicokinetics in toxicology and risk assessment. *Journal of Toxicology and Environmental Health - Part B: Critical Reviews*, **2003**, 6, 1-40	8.6	29
287	Dermal absorption of dihalomethane vapors. *Toxicology and Applied Pharmacology*, **1985**, 79, 150-8	4.6	29
286	Isoniazid suppresses antioxidant response element activities and impairs adipogenesis in mouse and human preadipocytes. *Toxicology and Applied Pharmacology*, **2013**, 273, 435-41	4.6	28

285	Oral absorption and oxidative metabolism of atrazine in rats evaluated by physiological modeling approaches. *Toxicology*, **2007**, 240, 1-14	4.4	28
284	Pharmacokinetic modeling of manganese. I. Dose dependencies of uptake and elimination. *Journal of Toxicology and Environmental Health - Part A: Current Issues*, **2007**, 70, 1493-504	3.2	28
283	Applying mode-of-action and pharmacokinetic considerations in contemporary cancer risk assessments: an example with trichloroethylene. *Critical Reviews in Toxicology*, **2004**, 34, 385-445	5.7	28
282	Quantitative bias analysis for epidemiological associations of perfluoroalkyl substance serum concentrations and early onset of menopause. *Environment International*, **2017**, 99, 245-254	12.9	27
281	Divergent effects of sulforaphane on basal and glucose-stimulated insulin secretion in Ŧcells: role of reactive oxygen species and induction of endogenous antioxidants. *Pharmaceutical Research*, **2013**, 30, 2248-59	4.5	27
280	Organic extract contaminants from drinking water activate Nrf2-mediated antioxidant response in a human cell line. *Environmental Science & Technology*, **2013**, 47, 4768-77	10.3	27
279	Evaluating pharmacokinetic and pharmacodynamic interactions with computational models in supporting cumulative risk assessment. *International Journal of Environmental Research and Public Health*, **2011**, 8, 1613-30	4.6	27
278	Kinetics of selected di-n-butyl phthalate metabolites and fetal testosterone following repeated and single administration in pregnant rats. *Toxicology*, **2009**, 255, 80-90	4.4	27
277	Kinetic characterization of CYP2E1 inhibition in vivo and in vitro by the chloroethylenes. *Archives of Toxicology*, **1998**, 72, 609-21	5.8	27
276	Inhalation dosimetry modeling with decamethylcyclopentasiloxane in rats and humans. *Toxicological Sciences*, **2008**, 105, 275-85	4.4	27
275	Molecular circuits, biological switches, and nonlinear dose-response relationships. *Environmental Health Perspectives*, **2002**, 110 Suppl 6, 971-8	8.4	27
274	Quantitative identification of atrazine and its chlorinated metabolites in plasma. *Journal of Analytical Toxicology*, **2003**, 27, 569-73	2.9	27
273	Using human data to protect the public's health. *Regulatory Toxicology and Pharmacology*, **2001**, 33, 234-56	3.4	27
272	Endocrine active compounds: from biology to dose response assessment. *Critical Reviews in Toxicology*, **1998**, 28, 363-423	5.7	27
271	Oral toxicity of 1,1-dichloroethylene in the rat: effects of sex, age, and fasting. *Environmental Health Perspectives*, **1977**, 21, 157-63	8.4	27
270	Contributions of DNA repair and damage response pathways to the non-linear genotoxic responses of alkylating agents. *Mutation Research - Reviews in Mutation Research*, **2016**, 767, 77-91	7	26
269	Suppression of NRF2-ARE activity sensitizes chemotherapeutic agent-induced cytotoxicity in human acute monocytic leukemia cells. *Toxicology and Applied Pharmacology*, **2016**, 292, 1-7	4.6	26
268	Assessing dose-dependent differences in DNA-damage, p53 response and genotoxicity for quercetin and curcumin. *Toxicology in Vitro*, **2013**, 27, 1877-87	3.6	26

267	Are highly lipophilic volatile compounds expected to bioaccumulate with repeated exposures?. *Toxicology Letters*, **2008**, 179, 85-92	4.4	26
266	Progestin receptor expression in the developing rat brain depends upon activation of estrogen receptor alpha and not estrogen receptor beta. *Brain Research*, **2006**, 1082, 50-60	3.7	26
265	Use of a pharmacokinetic-driven computational fluid dynamics model to predict nasal extraction of hydrogen sulfide in rats and humans. *Toxicological Sciences*, **2006**, 94, 359-67	4.4	26
264	1,1-Dichloroethylene nephrotoxicity in the rat. *Toxicology and Applied Pharmacology*, **1978**, 46, 131-41	4.6	26
263	A hybrid CFD-PBPK model for naphthalene in rat and human with IVIVE for nasal tissue metabolism and cross-species dosimetry. *Inhalation Toxicology*, **2014**, 26, 333-44	2.7	25
262	Cross-species transcriptomic analysis of mouse and rat lung exposed to chloroprene. *Toxicological Sciences*, **2013**, 131, 629-40	4.4	25
261	Multi-dose-route, multi-species pharmacokinetic models for manganese and their use in risk assessment. *Journal of Toxicology and Environmental Health - Part A: Current Issues*, **2010**, 73, 217-34	3.2	25
260	On the incorporation of chemical-specific information in risk assessment. *Toxicology Letters*, **2008**, 180, 100-9	4.4	25
259	Development of a physiologically based pharmacokinetic model for volatile fractions of gasoline using chemical lumping analysis. *Environmental Science & Technology*, **2004**, 38, 5674-81	10.3	25
258	Route-specific differences in distribution characteristics of octamethylcyclotetrasiloxane in rats: analysis using PBPK models. *Toxicological Sciences*, **2003**, 71, 41-52	4.4	25
257	Harmonization: Developing Consistent Guidelines for Applying Mode of Action and Dosimetry Information to Cancer and Noncancer Risk Assessment. *Human and Ecological Risk Assessment (HERA)*, **1998**, 4, 75-115	4.9	25
256	A dose response study to assess effects after dietary administration of diisononyl phthalate (DINP) in gestation and lactation on male rat sexual development. *Reproductive Toxicology*, **2013**, 35, 70-80	3.4	24
255	Editor's Highlight: Screening ToxCast Prioritized Chemicals for PPARG Function in a Human Adipose-Derived Stem Cell Model of Adipogenesis. *Toxicological Sciences*, **2017**, 155, 85-100	4.4	24
254	Identification of Nrf2-dependent airway epithelial adaptive response to proinflammatory oxidant-hypochlorous acid challenge by transcription profiling. *American Journal of Physiology - Lung Cellular and Molecular Physiology*, **2008**, 294, L469-77	5.8	24
253	Mechanistic approaches for mixture risk assessments-present capabilities with simple mixtures and future directions. *Environmental Toxicology and Pharmacology*, **2004**, 16, 1-11	5.8	24
252	Dose-response modeling in reproductive toxicology in the systems biology era. *Reproductive Toxicology*, **2005**, 19, 327-37	3.4	24
251	Dose-response characteristics of uterine responses in rats exposed to estrogen agonists. *Regulatory Toxicology and Pharmacology*, **1998**, 28, 133-49	3.4	24
250	Biological regulation of receptor-hormone complex concentrations in relation to dose-response assessments for endocrine-active compounds. *Toxicological Sciences*, **1999**, 48, 38-50	4.4	24

249	Hepatocyte-specific Nrf2 deficiency mitigates high-fat diet-induced hepatic steatosis: Involvement of reduced PPARexpression. *Redox Biology*, **2020**, 30, 101412	11.3	24
248	Disposition of diisononyl phthalate and its effects on sexual development of the male fetus following repeated dosing in pregnant rats. *Reproductive Toxicology*, **2013**, 35, 56-69	3.4	23
247	Physiologically based pharmacokinetic/toxicokinetic modeling. *Methods in Molecular Biology*, **2012**, 929, 439-99	1.4	23
246	Measurement of tumor-associated mutations in the nasal mucosa of rats exposed to varying doses of formaldehyde. *Regulatory Toxicology and Pharmacology*, **2010**, 57, 274-83	3.4	23
245	Hepatic sequestration of chlordecone and hexafluoroacetone evaluated by pharmacokinetic modeling. *Toxicology*, **2007**, 234, 59-72	4.4	23
244	Bayesian estimation of pharmacokinetic and pharmacodynamic parameters in a mode-of-action-based cancer risk assessment for chloroform. *Risk Analysis*, **2007**, 27, 1535-51	3.9	23
243	PB-PK derived metabolic constants, hepatotoxicity, and lethality of BrCCl3 in rats pretreated with chlordecone, phenobarbital, or mirex. *Toxicology and Applied Pharmacology*, **1991**, 109, 514-28	4.6	23
242	Mutagenicity of 2,3,7,8-tetrachlorodibenzo-p-dioxin and perfluoro-n-decanoic acid in L5178Y mouse-lymphoma cells. *Mutation Research-Fundamental and Molecular Mechanisms of Mutagenesis*, **1982**, 105, 445-9		23
241	The distribution and metabolism of cyclotrimethylenetrinitramine (RDX) in the rat after subchronic administration. *Toxicology and Applied Pharmacology*, **1978**, 46, 163-71	4.6	23
240	Assessing molecular initiating events (MIEs), key events (KEs) and modulating factors (MFs) for styrene responses in mouse lungs using whole genome gene expression profiling following 1-day and multi-week exposures. *Toxicology and Applied Pharmacology*, **2017**, 335, 28-40	4.6	22
239	A physiologically based pharmacokinetic model for lactational transfer of PCB 153 with or without PCB 126 in mice. *Archives of Toxicology*, **2007**, 81, 101-11	5.8	22
238	Pharmacokinetic modeling of manganese. III. Physiological approaches accounting for background and tracer kinetics. *Journal of Toxicology and Environmental Health - Part A: Current Issues*, **2007**, 70, 1515-26	3.2	22
237	Biologically Based, Quantitative Risk Assessment of Neurotoxicants. *Fundamental and Applied Toxicology*, **1996**, 29, 18-30		22
236	The inhalation toxicity of sulfolane (tetrahydrothiophene-1,1-dioxide). *Toxicology and Applied Pharmacology*, **1977**, 40, 463-72	4.6	22
235	The application of PBPK models in estimating human brain tissue manganese concentrations. *NeuroToxicology*, **2017**, 58, 226-237	4.4	21
234	Long isoforms of NRF1 negatively regulate adipogenesis via suppression of PPARexpression. *Redox Biology*, **2020**, 30, 101414	11.3	21
233	PBPK Model for Atrazine and Its Chlorotriazine Metabolites in Rat and Human. *Toxicological Sciences*, **2016**, 150, 441-53	4.4	21
232	Water pollutant fingerprinting tracks recent industrial transfer from coastal to inland China: a case study. *Scientific Reports*, **2013**, 3, 1031	4.9	21

231	Lactational transfer of manganese in rats: predicting manganese tissue concentration in the dam and pups from inhalation exposure with a pharmacokinetic model. *Toxicological Sciences*, **2009**, 112, 23-43	4.4	21
230	The effect of pregnancy on renal clearance of boron in rats given boric acid orally. *Toxicological Sciences*, **2001**, 60, 257-63	4.4	21
229	A Model for Pharmacokinetics and Physiological Feedback among Hormones of the Testicular-Pituitary Axis in Adult Male Rats: A Framework for Evaluating Effects of Endocrine Active Compounds. *Toxicological Sciences*, **1998**, 45, 174-187	4.4	21
228	Prediction of in vivo kinetic constants for metabolism of inhaled vapors from kinetic constants measured in vitro. *Fundamental and Applied Toxicology*, **1981**, 1, 403-9		21
227	Dose-response modeling of cytochrome p450 induction in rats by octamethylcyclotetrasiloxane. *Toxicological Sciences*, **2002**, 67, 159-72	4.4	20
226	Effect of dose, time, and pretreatment on the biliary excretion and tissue distribution of 2,3,7,8-tetrachlorodibenzo-p-dioxin in the rat. *Fundamental and Applied Toxicology*, **1993**, 21, 405-11		20
225	Dioxin hepatic carcinogenesis: biologically motivated modeling and risk assessment. *Toxicology Letters*, **1993**, 68, 177-89	4.4	20
224	Adipocyte-specific deficiency of Nfe2l1 disrupts plasticity of white adipose tissues and metabolic homeostasis in mice. *Biochemical and Biophysical Research Communications*, **2018**, 503, 264-270	3.4	20
223	Evaluating opportunities for advancing the use of alternative methods in risk assessment through the development of fit-for-purpose in vitro assays. *Toxicology in Vitro*, **2018**, 48, 310-317	3.6	19
222	Development of an in vitro high content imaging assay for quantitative assessment of CAR-dependent mouse, rat, and human primary hepatocyte proliferation. *Toxicology in Vitro*, **2016**, 36, 224-237	3.6	19
221	Dose-response modeling of etoposide-induced DNA damage response. *Toxicological Sciences*, **2014**, 137, 371-84	4.4	19
220	Stochastic modeling of B lymphocyte terminal differentiation and its suppression by dioxin. *BMC Systems Biology*, **2010**, 4, 40	3.5	19
219	Refined PBPK model of aggregate exposure to methyl tertiary-butyl ether. *Toxicology Letters*, **2007** , 169, 222-35	4.4	19
218	Single cell analysis of switch-like induction of CYP1A1 in liver cell lines. *Toxicological Sciences*, **2004**, 78, 287-94	4.4	19
217	Requirements for a Biologically Realistic Cancer Risk Assessment for Inorganic Arsenic. *International Journal of Toxicology*, **1999**, 18, 131-147	2.4	19
216	Pharmacokinetic modeling of 2,4-dichlorophenoxyacetic acid (2,4-D) in rat and in rabbit brain following single dose administration. *Toxicology Letters*, **1994**, 74, 189-201	4.4	19
215	An inhalation distribution model for the lactating mother and nursing child. *Toxicology Letters*, **1988** , 43, 23-9	4.4	19
214	Mode-of-action-based dosimeters for interspecies extrapolation of vinyl acetate inhalation risk. *Inhalation Toxicology*, **2001**, 13, 377-96	2.7	19

213	Derivation of an inhalation reference concentration based upon olfactory neuronal loss in male rats following subchronic acetaldehyde inhalation. *Inhalation Toxicology*, **2008**, 20, 245-56	2.7	18
212	Identification of a novel hemoglobin adduct in Sprague Dawley rats exposed to atrazine. *Chemical Research in Toxicology*, **2006**, 19, 692-700	4	18
211	Regional induction of CYP1A1 in rat liver following treatment with mixtures of PCB 126 and PCB 153. *Toxicologic Pathology*, **2004**, 32, 467-73	2.1	18
210	Dichloroacetate (DCA) dosimetry: interpreting DCA-induced liver cancer dose response and the potential for DCA to contribute to trichloroethylene-induced liver cancer. *Toxicology Letters*, **1999**, 106, 9-21	4.4	18
209	Sensitivity Analysis and the Design of Gas Uptake Inhalation Studies. *Inhalation Toxicology*, **1995**, 7, 1075-1094	2.1	18
208	Physiologically Based Pharmacokinetic Modeling of Chemical Mixtures **1994**, 399-437		18
207	Based on an analysis of mode of action, styrene-induced mouse lung tumors are not a human cancer concern. *Regulatory Toxicology and Pharmacology*, **2018**, 95, 17-28	3.4	17
206	Information-dependent enrichment analysis reveals time-dependent transcriptional regulation of the estrogen pathway of toxicity. *Archives of Toxicology*, **2017**, 91, 1749-1762	5.8	17
205	Application of a multi-route physiologically based pharmacokinetic model for manganese to evaluate dose-dependent neurological effects in monkeys. *Toxicological Sciences*, **2012**, 129, 432-46	4.4	17
204	Derivation of a drinking water equivalent level (DWEL) related to the maximum contaminant level goal for perfluorooctanoic acid (PFOA), a persistent water soluble compound. *Food and Chemical Toxicology*, **2009**, 47, 2557-89	4.7	17
203	Pharmacokinetic modeling of manganese. II. Hepatic processing after ingestion and inhalation. *Journal of Toxicology and Environmental Health - Part A: Current Issues*, **2007**, 70, 1505-14	3.2	17
202	PBPK modeling/Monte Carlo simulation of methylene chloride kinetic changes in mice in relation to age and acute, subchronic, and chronic inhalation exposure. *Environmental Health Perspectives*, **1996**, 104, 858-65	8.4	17
201	Recent advances in methodology and concepts for characterizing inhalation pharmacokinetic parameters in animals and man. *Drug Metabolism Reviews*, **1982**, 13, 799-826	7	17
200	Editor's Highlight: Complete Attenuation of Mouse Lung Cell Proliferation and Tumorigenicity in CYP2F2 Knockout and CYP2F1 Humanized Mice Exposed to Inhaled Styrene for up to 2 Years Supports a Lack of Human Relevance. *Toxicological Sciences*, **2017**, 159, 413-421	4.4	16
199	Dose-response approaches for nuclear receptor-mediated modes of action for liver carcinogenicity: Results of a workshop. *Critical Reviews in Toxicology*, **2014**, 44, 50-63	5.7	16
198	U.S. Environmental Protection Agency's revised cancer guidelines for carcinogen risk assessment. *Toxicology and Applied Pharmacology*, **1998**, 153, 133-6	4.6	16
197	Development of a physiologically based pharmacokinetic model for 2,4-dichlorophenoxyacetic acid dosimetry in discrete areas of the rabbit brain. *Neurotoxicology and Teratology*, **1995**, 17, 111-20	3.9	16
196	Physiologically based pharmacokinetic (PB-PK) models in the study of the disposition and biological effects of xenobiotics and drugs. *Toxicology Letters*, **1995**, 82-83, 341-8	4.4	16

195	Lessons learned, challenges, and opportunities: the U.S. Endocrine Disruptor Screening Program. *ALTEX: Alternatives To Animal Experimentation*, **2014**, 31, 63-78	4.3	16
194	Combining transcriptomics and PBPK modeling indicates a primary role of hypoxia and altered circadian signaling in dichloromethane carcinogenicity in mouse lung and liver. *Toxicology and Applied Pharmacology*, **2017**, 332, 149-158	4.6	15
193	Multiple receptors shape the estrogen response pathway and are critical considerations for the future of in vitro-based risk assessment efforts. *Critical Reviews in Toxicology*, **2017**, 47, 564-580	5.7	15
192	Pharmacodynamic model of the rat estrus cycle in relation to endocrine disruptors. *Journal of Toxicology and Environmental Health - Part A: Current Issues*, **1997**, 52, 189-209	3.2	15
191	PBTK modeling demonstrates contribution of dermal and inhalation exposure components to end-exhaled breath concentrations of naphthalene. *Environmental Health Perspectives*, **2007**, 115, 894-901	8.4	15
190	Occupational exposure limits in the context of solvent mixtures, consumption of ethanol, and target tissue dose. *Toxicology and Industrial Health*, **2004**, 20, 165-75	1.8	15
189	PBPK modeling of complex hydrocarbon mixtures: gasoline. *Environmental Toxicology and Pharmacology*, **2004**, 16, 107-19	5.8	15
188	What do we Mean by Dose. *Inhalation Toxicology*, **1995**, 7, 909-915	2.7	15
187	All-or-none suppression of B cell terminal differentiation by environmental contaminant 2,3,7,8-tetrachlorodibenzo-p-dioxin. *Toxicology and Applied Pharmacology*, **2013**, 268, 17-26	4.6	14
186	Update on a Pharmacokinetic-Centric Alternative Tier II Program for MMT-Part II: Physiologically Based Pharmacokinetic Modeling and Manganese Risk Assessment. *Journal of Toxicology*, **2012**, 2012, 791431	3.1	14
185	A dermatotoxicokinetic model of human exposures to jet fuel. *Toxicological Sciences*, **2006**, 93, 22-33	4.4	14
184	The acute toxicity of single, oral doses of 1,1-dichloroethylene in the fasted, male rat: effect of induction and inhibition of microsomal enzyme activities on mortality. *Toxicology and Applied Pharmacology*, **1978**, 46, 227-34	4.6	14
183	Approaches for characterizing threshold dose-response relationships for DNA-damage pathways involved in carcinogenicity in vivo and micronuclei formation in vitro. *Mutagenesis*, **2016**, 31, 333-40	2.8	13
182	Development of 3D dynamic flow model of human liver and its application to prediction of metabolic clearance of 7-ethoxycoumarin. *Tissue Engineering - Part C: Methods*, **2014**, 20, 641-51	2.9	13
181	Ethyl acrylate risk assessment with a hybrid computational fluid dynamics and physiologically based nasal dosimetry model. *Toxicological Sciences*, **2004**, 79, 394-403	4.4	13
180	Induction of CYP1A1 in primary rat hepatocytes by 3,3',4,4',5-pentachlorobiphenyl: evidence for a switch circuit element. *Toxicological Sciences*, **2004**, 78, 276-86	4.4	13
179	Stochastic simulation of hepatic preneoplastic foci development for four chlorobenzene congeners in a medium-term bioassay. *Toxicological Sciences*, **2003**, 73, 301-14	4.4	13
178	Closed-chamber inhalation pharmacokinetic studies with hexamethyldisiloxane in the rat. *Inhalation Toxicology*, **2003**, 15, 589-617	2.7	13

177	Mechanistic modeling of rodent liver tumor promotion at low levels of exposure: an example related to dose-response relationships for 2,3,7,8-tetrachlorodibenzo-p-dioxin. *Human and Experimental Toxicology*, **1998**, 17, 683-90; discussion 701-4, 708-18	3.4	13
176	Development of an integrated multi-species and multi-dose route PBPK model for volatile methyl siloxanes - D4 and D5. *Regulatory Toxicology and Pharmacology*, **2016**, 74 Suppl, S1-13	3.4	13
175	A pharmacokinetic model describing pulsatile uptake of orally-administered carbon tetrachloride. *Toxicology*, **1997**, 117, 25-33	4.4	12
174	3-chlorotyrosine and 3,5-dichlorotyrosine as biomarkers of respiratory tract exposure to chlorine gas. *Journal of Analytical Toxicology*, **2008**, 32, 99-105	2.9	12
173	Binary gene induction and protein expression in individual cells. *Theoretical Biology and Medical Modelling*, **2006**, 3, 18	2.3	12
172	A comparison of the toxicology of triethylene glycol dinitrate and propylene glycol dinitrate. *AIHA Journal*, **1973**, 34, 526-32		12
171	Fluid Dynamic Modeling to Support the Development of Flow-Based Hepatocyte Culture Systems for Metabolism Studies. *Frontiers in Bioengineering and Biotechnology*, **2016**, 4, 72	5.8	12
170	A tissue dose-based comparative exposure assessment of manganese using physiologically based pharmacokinetic modeling-The importance of homeostatic control for an essential metal. *Toxicology and Applied Pharmacology*, **2017**, 322, 27-40	4.6	11
169	Considerations for refining the risk assessment process for formaldehyde: Results from an interdisciplinary workshop. *Regulatory Toxicology and Pharmacology*, **2019**, 106, 210-223	3.4	11
168	Using gene expression profiling to evaluate cellular responses in mouse lungs exposed to V2O5 and a group of other mouse lung tumorigens and non-tumorigens. *Regulatory Toxicology and Pharmacology*, **2015**, 73, 339-47	3.4	11
167	Differential Effects of Trovafloxacin on TNF-□and IL-6 Profiles in a Rat Hepatocyte□Kupffer Cell Coculture System. *Applied in Vitro Toxicology*, **2015**, 1, 45-54	1.3	11
166	Pollution trees: identifying similarities among complex pollutant mixtures in water and correlating them to mutagenicity. *Environmental Science & Technology*, **2012**, 46, 7274-82	10.3	11
165	Assessing kinetic determinants for metabolism and oral uptake of octamethylcyclotetrasiloxane (D4) from inhalation chamber studies. *Inhalation Toxicology*, **2008**, 20, 361-73	2.7	11
164	Pharmacokinetic modeling approaches for describing the uptake, systemic distribution, and disposition of inhaled chemicals. *Critical Reviews in Toxicology*, **1995**, 25, 237-54	5.7	11
163	Improving toxicology testing protocols using computer simulations. *Toxicology Letters*, **1989**, 49, 139-58	4.4	11
162	Building shared experience to advance practical application of pathway-based toxicology: liver toxicity mode-of-action. *ALTEX: Alternatives To Animal Experimentation*, **2014**, 31, 500-19	4.3	11
161	Developing context appropriate toxicity testing approaches using new alternative methods (NAMs). *ALTEX: Alternatives To Animal Experimentation*, **2019**, 36, 523-534	4.3	11
160	Pharmacokinetic bias analysis of the epidemiological associations between serum polybrominated diphenyl ether (BDE-47) and timing of menarche. *Environmental Research*, **2016**, 150, 541-548	7.9	11

159	Embracing Systems Toxicology at Single-Cell Resolution. *Current Opinion in Toxicology*, **2019**, 16, 49-57	4.4	10
158	Severity scoring of manganese health effects for categorical regression. *NeuroToxicology*, **2017**, 58, 203-216	4.1	10
157	Cancer and non-cancer risk assessment should be harmonized. *Human and Ecological Risk Assessment (HERA)*, **1997**, 3, 495-499	4.9	10
156	Thresholds of carcinogenicity in the ED01 study. *Toxicological Sciences*, **2003**, 74, 486-7; author reply 487-8	4.4	10
155	Evidence of a "clear and consistent threshold" for bladder and liver cancer in the large ED01 carcinogenicity study. *Toxicological Sciences*, **2003**, 74, 485; author reply 485-6	4.4	10
154	Probing the control elements of the CYP1A1 switching module in H4IIE hepatoma cells. *Toxicological Sciences*, **2005**, 88, 82-94	4.4	10
153	Comparing respiratory-tract and hepatic exposure-dose relationships for metabolized inhaled vapors: a pharmacokinetic analysis. *Inhalation Toxicology*, **2002**, 14, 835-54	2.7	10
152	A physiologically-based pharmacokinetic model for 2,3,7,8-tetrachlorodibenzo-p-dioxin. *Chemosphere*, **1989**, 18, 659-664	8.4	10
151	Strain-related differences in mouse lung gene expression over a two-year period of inhalation exposure to styrene: Relevance to human risk assessment. *Regulatory Toxicology and Pharmacology*, **2018**, 96, 153-166	3.4	10
150	Quantitative bias analysis of a reported association between perfluoroalkyl substances (PFAS) and endometriosis: The influence of oral contraceptive use. *Environment International*, **2017**, 104, 118-121	12.9	9
149	PBPK-Based Probabilistic Risk Assessment for Total Chlorotriazines in Drinking Water. *Toxicological Sciences*, **2016**, 150, 269-82	4.4	9
148	Deriving an explicit hepatic clearance equation accounting for plasma protein binding and hepatocellular uptake. *Toxicology in Vitro*, **2013**, 27, 11-5	3.6	9
147	Inhalation dosimetry of hexamethylene diisocyanate vapor in the rat and human respiratory tracts. *Inhalation Toxicology*, **2013**, 25, 168-77	2.7	9
146	Experimental exposure to 1,1,1,3,3-pentafluoropropane (HFC-245fa): uptake and disposition in humans. *Toxicological Sciences*, **2010**, 113, 326-36	4.4	9
145	Dose-response assessment strategies for endocrine-active compounds. *Regulatory Toxicology and Pharmacology*, **1997**, 25, 292-305	3.4	9
144	Development of an immunochemical detection method for atrazine-induced albumin adducts. *Chemical Research in Toxicology*, **2007**, 20, 1061-6	4	9
143	Polychlorotrifluoroethylene (PCTFE) oligomer pharmacokinetics in Fischer 344 rats: development of a physiologically based model. *Fundamental and Applied Toxicology*, **1992**, 18, 504-14		9
142	Tissue dosimetry, physiologically-based pharmacokinetic modeling, and cancer risk assessment. *Cell Biology and Toxicology*, **1989**, 5, 405-15	7.4	9

141	Mechanistic modeling of rodent liver tumor promotion at low levels of exposure: an example related to dose-response relationships for 2,3,7,8-tetrachlorodibenzo-p-dioxi. *Human and Experimental Toxicology*, **1998**, 17, 683-690	3.4	9
140	Physiologically based clearance/extraction models for compounds metabolized in the nose: an example with methyl methacrylate. *Inhalation Toxicology*, **2001**, 13, 397-414	2.7	9
139	Interspecies Scaling in Pharmacokinetics **1991**, 203-226		9
138	Bioactivation and toxicity of acetaminophen in a rat hepatocyte micropatterned coculture system. *Journal of Biochemical and Molecular Toxicology*, **2013**, 27, 471-8	3.4	8
137	Update on a Pharmacokinetic-Centric Alternative Tier II Program for MMT-Part I: Program Implementation and Lessons Learned. *Journal of Toxicology*, **2012**, 2012, 946742	3.1	8
136	Physiologically Based Pharmacokinetic and Toxicokinetic Models **2007**, 231-292		8
135	Pitfalls and related improvements of in vivo gas uptake pharmacokinetic experimental systems. *Inhalation Toxicology*, **2005**, 17, 539-48	2.7	8
134	An improved approximation to the exact solution of the two-stage clonal growth model of cancer. *Risk Analysis*, **1995**, 15, 467-73	3.9	8
133	Development of a mechanism-based dosimetry model for 2,4,4-trimethyl-2-pentanol-induced alpha 2u-globulin nephropathy in male Fischer 344 rats. *Fundamental and Applied Toxicology*, **1995**, 25, 124-37		8
132	A perspective on biologically-based approaches to dioxin risk assessment. *Risk Analysis*, **1991**, 11, 565-8	3.9	8
131	A Risk Assessment Approach for Nursing Infants Exposed to Volatile Organics through the Mother's Occupational Inhalation Exposure. *Applied Industrial Hygiene*, **1989**, 4, 21-26		8
130	Gene co-regulation and co-expression in the aryl hydrocarbon receptor-mediated transcriptional regulatory network in the mouse liver. *Archives of Toxicology*, **2020**, 94, 113-126	5.8	8
129	A toxicogenomic approach for the risk assessment of the food contaminant acetamide. *Toxicology and Applied Pharmacology*, **2020**, 388, 114872	4.6	8
128	Addressing systematic inconsistencies between in vitro and in vivo transcriptomic mode of action signatures. *Toxicology in Vitro*, **2019**, 58, 1-12	3.6	8
127	Pathway Based Toxicology and Fit-for-Purpose Assays. *Advances in Experimental Medicine and Biology*, **2016**, 856, 205-230	3.6	7
126	Editor's Highlight: Development of an In vitro Assay Measuring Uterine-Specific Estrogenic Responses for Use in Chemical Safety Assessment. *Toxicological Sciences*, **2016**, 154, 162-173	4.4	7
125	Keap1 silencing boosts lipopolysaccharide-induced transcription of interleukin 6 via activation of nuclear factor B in macrophages. *Toxicology and Applied Pharmacology*, **2013**, 272, 697-702	4.6	7
124	Response to Incorporating Biological, Chemical, and Toxicological Knowledge Into Predictive Models of Toxicity *Toxicological Sciences*, **2012**, 130, 442-443	4.4	7

123	Data-Derived Uncertainty Factors: Boric Acid (BA) as a Case Study. *Human and Ecological Risk Assessment (HERA)*, **2001**, 7, 125-138	4.9	7
122	Under What Conditions Is Trichloroethylene Likely To Be a Carcinogen in Humans?. *Human and Ecological Risk Assessment (HERA)*, **2001**, 7, 687-716	4.9	7
121	Use of a Physiologically Based Pharmacokinetic Model and Computer Simulation for Retrospective Assessment of Exposure to Volatile Toxicants. *Inhalation Toxicology*, **1990**, 2, 119-128	2.7	7
120	Enhancement of 1,1-dichloroethylene toxicity by pretreatment of fasted male rats with 2,3-epoxypropan-1-ol. *Drug and Chemical Toxicology*, **1977**, 1, 63-74	2.3	7
119	Identifying qualitative differences in PPARβ signaling networks in human and rat hepatocytes and their significance for next generation chemical risk assessment methods. *Toxicology in Vitro*, **2020**, 64, 104463	3.6	7
118	Application of a combined aggregate exposure pathway and adverse outcome pathway (AEP-AOP) approach to inform a cumulative risk assessment: A case study with phthalates. *Toxicology in Vitro*, **2020**, 66, 104855	3.6	7
117	Risk science in the 21st century: a data-driven framework for incorporating new technologies into chemical safety assessment. *International Journal of Risk Assessment and Management*, **2017**, 20, 88	0.9	6
116	Liquid-air partition coefficients of 1,1-difluoroethane (HFC152a), 1,1,1-trifluoroethane (HFC143a), 1,1,1,2-tetrafluoroethane (HFC134a), 1,1,1,2,2-pentafluoroethane (HFC125) and 1,1,1,3,3-pentafluoropropane (HFC245fa). *Journal of Applied Toxicology*, **2010**, 30, 59-62	4.1	6
115	A model for pharmacokinetics and physiological feedback among hormones of the testicular-pituitary axis in adult male rats: a framework for evaluating effects of endocrine active compounds. *Toxicological Sciences*, **1998**, 45, 174-87	4.4	6
114	Dose-incidence modeling: consequences of linking quantal measures of response to depletion of critical tissue targets. *Toxicological Sciences*, **2006**, 89, 331-7	4.4	6
113	Improving Risk Assessment: Research Opportunities in Dose Response Modeling to Improve Risk Assessment. *Human and Ecological Risk Assessment (HERA)*, **2002**, 8, 1421-1444	4.9	6
112	Perfluoro-N-decanoic acid effects on enzymes of fatty acid metabolism. *Toxicology Letters*, **1990**, 54, 39-46	4.4	6
111	The role of fit-for-purpose assays within tiered testing approaches: A case study evaluating prioritized estrogen-active compounds in an in vitro human uterotrophic assay. *Toxicology and Applied Pharmacology*, **2020**, 387, 114774	4.6	6
110	The Human Toxome Collaboratorium: A Shared Environment for Multi-Omic Computational Collaboration within a Consortium. *Frontiers in Pharmacology*, **2015**, 6, 322	5.6	6
109	Incorporation of metabolism data and physiologically based pharmacokinetic modeling in a risk assessment for chloroprene. *Inhalation Toxicology*, **2019**, 31, 468-483	2.7	6
108	Assessing bioactivity-exposure profiles of fruit and vegetable extracts in the BioMAP profiling system. *Toxicology in Vitro*, **2019**, 54, 41-57	3.6	6
107	Application of transcriptomic data, visualization tools and bioinformatics resources for informing mode of action. *Current Opinion in Toxicology*, **2018**, 9, 21-27	4.4	6
106	Refinement of the oral exposure description in the cyclic siloxane PBPK model for rats and humans: Implications for exposure assessment. *Toxicology Letters*, **2017**, 279 Suppl 1, 125-135	4.4	5

105	Predicting cytotoxicity of complex mixtures in high cancer incidence regions of the Huai River Basin based on GC-MS spectrum with partial least squares regression. *Environmental Research*, **2015**, 137, 391-7	7.9	5
104	Estimating constants for metabolism of atrazine in freshly isolated rat hepatocytes by kinetic modeling. *Toxicology in Vitro*, **2007**, 21, 492-501	3.6	5
103	Further comments on the bioavailability of D4. *Environmental Health Perspectives*, **2002**, 110, A444-5; author reply A445-8	8.4	5
102	1988 Herbert E. Stokinger Lecture: Quantitative Risk Assessment and Occupational Carcinogens. *Applied Industrial Hygiene*, **1988**, 3, 267-273		5
101	On the mechanism of the oxidation of human and rat hemoglobin by propylene glycol dinitrate. *Biochemical Pharmacology*, **1973**, 22, 3247-56	6	5
100	Using quantitative modeling tools to assess pharmacokinetic bias in epidemiological studies showing associations between biomarkers and health outcomes at low exposures. *Environmental Research*, **2021**, 197, 111183	7.9	5
99	Xenobiotic Metabolism in Alginate-Encapsulated Primary Human Hepatocytes Over Long Timeframes. *Applied in Vitro Toxicology*, **2018**, 4, 238-247	1.3	5
98	Physiologically Based Modeling of Pharmacokinetic Interactions in Chemical Mixtures83-105		5
97	Combined exposure to 3-chloro-4-dichloromethyl-5-hydroxy-2(5H)-furanone and microsytin-LR increases genotoxicity in Chinese hamster ovary cells through oxidative stress. *Environmental Science & Technology*, **2013**, 47, 1678-87	10.3	4
96	Toxicokinetic Models: Where We've Been and Where We Need to Go!. *Human and Ecological Risk Assessment (HERA)*, **2002**, 8, 1375-1395	4.9	4
95	The effects of perfluorodecanoic acid on hepatic stearoyl-coenzyme A desaturase and mixed function oxidase activities in rats. *Fundamental and Applied Toxicology*, **1988**, 11, 503-510		4
94	Some neurotoxic properties of triethylene glycol dinitrate: a comparison with decamethonium. *Toxicology and Applied Pharmacology*, **1976**, 36, 585-94	4.6	4
93	A Kinetic Analysis of DNA-Deoxy Guanine Adducts in the Nasal Epithelium Produced by Inhaled Formaldehyde in Rats-Assessing Contributions to Adduct Production From Both Endogenous and Exogenous Sources of Formaldehyde. *Toxicological Sciences*, **2020**, 177, 325-333	4.4	4
92	A Qualitative Modeling Approach for Whole Genome Prediction Using High-Throughput Toxicogenomics Data and Pathway-Based Validation. *Frontiers in Pharmacology*, **2018**, 9, 1072	5.6	4
91	Future directions in risk science. *International Journal of Risk Assessment and Management*, **2017**, 20, 240	0.9	3
90	In utero exposure to chloroquine alters sexual development in the male fetal rat. *Toxicology and Applied Pharmacology*, **2009**, 237, 366-74	4.6	3
89	The Use of Biochemical and Molecular Parameters to Estimate Dose-Response Relationships at Low Levels of Exposure. *Environmental Health Perspectives*, **1998**, 106, 349	8.4	3
88	Statistical Approaches to Identifying Androgen Response Elements **2007**,		3

87	Introduction: A Historical Perspective of the Development and Applications of PBPK Models **2005**, 1-18		3
86	Kinetic and mechanistic data needs for a human phsiologically based pharmacokinetic (PBPK) model for acrylamide: pharmacokinetic model for acrylamide. *Advances in Experimental Medicine and Biology*, **2005**, 561, 117-25	3.6	3
85	The use of quantitative histological and molecular data for risk assessment and biologically based model development. *Toxicologic Pathology*, **2002**, 30, 106-11	2.1	3
84	Quantitative Mechanistically Based Dose-Response Modeling with Endocrine-Active Compounds. *Environmental Health Perspectives*, **1999**, 107, 631	8.4	3
83	A pharmacokinetic model of anaerobic in vitro carbon tetrachloride metabolism. *Chemico-Biological Interactions*, **1996**, 101, 13-31	5	3
82	Physiological Modeling and Cancer Risk Assessment **1991**, 335-354		3
81	Biological and physiological factors involved in disposition of dioxin and related compounds. *Chemosphere*, **1992**, 25, 3-6	8.4	3
80	Physiologically Based Pharmacokinetic and Pharmacodynamic Modeling		3
79	Physiologically Based Pharmacokinetic and Toxicokinetic Models **2014**, 247-294		2
78	Prenatal PCB-153 Exposure and Decreased Birth Weight: Verner et al. Respond. *Environmental Health Perspectives*, **2014**, 122, A89-90	8.4	2
77	Comprehensive assessment of exposure to identify health consequences of e-waste. *The Lancet Global Health*, **2014**, 2, e73	13.6	2
76	Comment on M.V. Evans and J.C. Caldwell: evaluation of two different metabolic hypotheses for dichloromethane toxicity using physiologically based pharmacokinetic modeling of in vivo gas uptake data exposure in female B6C3F1 mice, Toxicol. Appl. Pharmacol., 244, 280-290, 2010. *Toxicology and Applied Pharmacology*, **2010**, 248, 63-4; author reply 65-7	4.6	2
75	Mixtures **2005**, 349-373		2
74	Improving Risk Assessment: Toxicological Research Needs. *Human and Ecological Risk Assessment (HERA)*, **2002**, 8, 1405-1419	4.9	2
73	. *Risk Analysis*, **1999**, 19, 9-14	3.9	2
72	The toxicity of single doses of N-nitrodimethylamine in rodents. *Drug and Chemical Toxicology*, **1978**, 1, 363-71	2.3	2
71	The genotoxic potential of mixed nitrosamines in drinking water involves oxidative stress and Nrf2 activation.. *Journal of Hazardous Materials*, **2021**, 426, 128010	12.8	2
70	Physiologically Based Pharmacokinetic Modeling1167-1227		2

69	Reactive Oxygen Species and Antioxidants in Pancreatic Cell Function Yin and Yang **2014**, 3319-3337		2
68	Application of the Risk Assessment Approaches in the USEPA Proposed Cancer Guidelines to Inorganic Arsenic **1999**, 99-111		2
67	Information-dependent Enrichment Analysis Reveals Time-dependent Transcriptional Regulation of the Estrogen Pathway of Toxicity		2
66	Why is elevation of serum cholesterol associated with exposure to perfluoroalkyl substances (PFAS) in humans? A workshop report on potential mechanisms. *Toxicology*, **2021**, 459, 152845	4.4	2
65	Physiologically-based pharmacokinetic modeling suggests similar bioavailability of Mn from diet and drinking water. *Toxicology and Applied Pharmacology*, **2018**, 359, 70-81	4.6	2
64	Ultrasensitive Response Motifs in Biochemical Networks199-217		2
63	The TTC Data Mart: An interactive browser for threshold of toxicological concern calculations. *Computational Toxicology*, **2020**, 15, 100128	3.1	1
62	Consideration of Styrene Transcriptomic Data Informs Mouse Lung Cyp2F2-Mediated Adverse Outcome Pathway. *Toxicological Sciences*, **2020**, 175, 3-4	4.4	1
61	Physiological Parameters and Databases for PBPK Modeling107-134		1
60	Physiologically Based Pharmacokinetic Modeling **2010**, 1		1
59	Implementation of EPA Revised Cancer Assessment Guidelines: Incorporation of Mechanistic and Pharmacokinetic Data. *Toxicological Sciences*, **1997**, 37, 16-36	4.4	1
58	Response to Comments by Caldwell et al. on Article Applying Mode-of-Action and Pharmacokinetic Considerations in Contemporary Cancer Risk Assessments: An Example with Trichloroethylene *Critical Reviews in Toxicology*, **2006**, 36, 295-298	5.7	1
57	Dermal Exposure Models **2005**, 375-387		1
56	Dermal Absorption of Organic Chemical Vapors in Rats and Humans. *Toxicological Sciences*, **1990**, 14, 299-308	4.4	1
55	PBPK Modeling: A Primer19-58		1
54	Gene Coregulation and Coexpression in the Aryl Hydrocarbon Receptor-mediated Transcriptional Regulatory Network in the Mouse Liver		1
53	A systematic approach to evaluate plausible modes of actions for mouse lung tumors in mice exposed to 4-methylimidozole. *Regulatory Toxicology and Pharmacology*, **2021**, 124, 104977	3.4	1
52	Time-dependent genomic response in primary human uroepithelial cells exposed to arsenite for up to 60 days. *Toxicology*, **2021**, 461, 152893	4.4	1

51	Quantitative Modeling in Toxicology: An Introduction1-18		1
50	Gene and Protein Expression Modeling Nested Motifs in Cellular and Tissue Response Networks219-233		1
49	Quantitative Modeling in Noncancer Risk Assessment371-398		1
48	Uncertainty, Variability, and Sensitivity Analyses in Simulation Models429-458		1
47	Bistable Signaling Motifs and Cell Fate Decisions181-198		1
46	Computer Simulation of Chemical Carcinogenesis **1989**, 301-317		1
45	Updating physiologically based pharmacokinetic models for manganese by incorporating rapid association/dissociation processes in tissues. *Toxicology and Applied Pharmacology*, **2019**, 372, 1-10	4.6	0
44	Modeling Kinetic Interactions of Chemical Mixtures **2010**, 125-157		0
43	Analysis of Transcriptomic DoseResponse Data for Toxicology and Risk Assessment **2011**, 237-250		0
42	Fate and effects of carbon nanotubes following inhalation118-133		0
41	Mode of Action Studies for Assessing Carcinogenic Risks Posed by Inorganic Arsenic **1999**, 397-406		0
40	Single enrichment systems possibly underestimate both exposures and biological effects of organic pollutants from drinking water.. *Chemosphere*, **2022**, 133496	8.4	0
39	Research Career Overview: An Interview With Dr Melvin (Mel) E. Andersen, the 2016 Mildred J. Christian Award Winner. *International Journal of Toxicology*, **2017**, 36, 4-7	2.4	
38	Chapter 13:Modeling Manganese Kinetics for Human Health Risk Assessment. *Issues in Toxicology*, **2014**, 322-354	0.3	
37	Role of Core Biological Motifs in DoseResponse Modeling: An Example with Switchlike Circuits **2011**, 147-173		
36	Pharmacokinetic Modeling of Manganese An Essential Element59-82		
35	Response to "Accurate Risk-Based Chemical Screening * Relies on Robust Exposure Estimates". *Toxicological Sciences*, **2012**, 128, 297-299	4.4	
34	Response to the Letter to the Editor: The Dose-Response Model for Dioxin *Risk Analysis*, **1998**, 18, 673-673	3.9	

33	Computational Systems Biology Modeling of Dosimetry and Cellular Response Pathways155-173	
32	Dioxin and Related Compounds **2005**, 207-237	
31	Halogenated Alkenes **2005**, 55-78	
30	Alkene and Aromatic Compounds **2005**, 79-117	
29	Reactive Vapors in the Nasal Cavity **2005**, 119-140	
28	Alkanes, Oxyhydrocarbons and Related Compounds **2005**, 141-166	
27	Pesticides and Persistent Organic Pollutants (POPs) **2005**, 167-205	
26	Halogenated Alkanes **2005**, 19-54	
25	Perinatal Pharmacokinetics **2005**, 319-347	
24	Dose Response Relationship in Anti-Stress Gene Regulatory Networks. *PLoS Computational Biology*, **2005**, preprint, e24	5
23	Comparisons of thresholds for carcinogenicity on linear and logarithmic dose scales. *Human and Experimental Toxicology*, **2005**, 24, 603-5; author reply 605-7	3.4
22	Biologically based risk assessment model for cyclophosphamide hematotoxicity in animal species: concluding comments. *Journal of Toxicology and Environmental Health - Part A: Current Issues*, **2000**, 61, 543-52	3.2
21	Development of a Mechanism-Based Dosimetry Model for 2,4,4-Trimethyl-2-pentanol-lnduced 2u-Globulin Nephropathy in Male Fischer 344 Rats. *Toxicological Sciences*, **1995**, 25, 124-137	4.4
20	Biologically Based, Quantitative Risk Assessment of Neurotoxicants. *Toxicological Sciences*, **1996**, 29, 18-30	4.4
19	Effect of Dose, Time, and Pretreatement on the Biliary Excretion and Tissue Distribution of 2,3,7,8-Tetrachlorodibenzo-p-dioxin in the Rat. *Toxicological Sciences*, **1993**, 21, 405-411	4.4
18	Polychlorotrifluoroethylene (PCTFE) Oligomer Pharmacokinetics in Fischer 344 Rats: Development of a Physiologically Based Model. *Toxicological Sciences*, **1992**, 18, 504-514	4.4
17	Pathological and Hepatic Ultrastructural Effects of a Single Dose of Perfluoro-n-decanoic Acid in the Rat, Hamster, Mouse, and Guinea Pig. *Toxicological Sciences*, **1987**, 9, 522-540	4.4
16	Prediction of In Vivo Kinetic Constants for Metabolism of Inhaled Vapors from Kinetic Constants Measured In Vitro. *Toxicological Sciences*, **1981**, 1, 403-409	4.4

15 Biologically Based Pharmacokinetics and Cancer Risk Assessment **1991**, 79-92

14 An Overview of the Outstanding Issues in the Risk Assessment of Methylene Chloride **1992**, 217-229

13 Nuclear Receptor-Mediated Gene Expression Changes in a Human Hepatic Micropatterned Coculture Model After Treatment with Hepatotoxic Compounds. *Applied in Vitro Toxicology*, **2016**, 2, 8-16 1.3

12 RNA-sequencing (transcriptomic) data collected in liver and lung of male and female B6C3F1 mice exposed to various dose levels of 4-methylimidazole for 2, 5, or 28 days. *Data in Brief*, **2021**, 38, 107420 1.2

11 Characterization of the Pharmacokinetics of Gasoline Using PBPK Modeling with a Complex Mixtures Chemical Lumping Approach. *Inhalation Toxicology*, **2003**, 15, 961-986 2.7

10 Modeling Liver and Kidney Cytotoxicity235-250

9 Computational Model for Iodide Economy and the HPT Axis in the Adult Rat251-267

8 Two-Stage Clonal Growth Modeling of Cancer269-282

7 Statistical and Physiological Modeling of the Toxicity of Chemicals in Mixtures283-297

6 (Q)SAR Models of Adverse Responses: Acute Systemic Toxicity299-314

5 Modeling Exposures to Chemicals from Multiple Sources and Routes315-351

4 Probabilistic Reverse Dosimetry Modeling for Interpreting Biomonitoring Data353-369

3 Evaluation of Quantitative Models in Toxicology: Progress and Challenges459-475

2 Modeling Cholinesterase Inhibition135-165

1 Modeling of Protein Induction and Dose-Dependent Hepatic Sequestration167-179